Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 19, 2012, Pages 7439-7444

  De Alwis, Ruklanthi ^a   Smith, Scott A ^b   Olivarez, Nicholas P ^a   Messer, William B ^a   Huynh, Jeremy P ^a   Wahala, Wahala M P B ^a   White, Laura J ^c   Diamond, Michael S ^d   Baric, Ralph S ^a   Crowe, James E ^b   De Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Global Vaccine Inc ^*  (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; EPITOPE MAPPING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN PURIFICATION; PROTEIN QUATERNARY STRUCTURE; VIRION; VIRUS MUTANT; VIRUS NEUTRALIZATION;

DENGUE VIRUS; FLAVIVIRUS;

EID: 84860826712     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1200566109     Document Type: Article

References (40)

1. Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: The spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10 (Suppl):S98-S109. (Pubitemid 40018233)
2. Beasley DWC, Barrett ADT (2008) The Infectious Agent, Dengue, Tropical Medicine: Science and Practice, eds Halstead SBP, Hoffman G (Imperial College Press, London), Vol 5, pp 29-73.
3. Imrie A, et al. (2007) Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 20:672-675.
4. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-467.
5. Roehrig JT (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141-175.
6. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH (2006) Crystal structure of the West Nile virus envelope glycoprotein. J Virol 80:11467-11474. (Pubitemid 44788862)
7. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:291-298.
8. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100:6986-6991. (Pubitemid 36706380)
9. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79:1223-1231. (Pubitemid 40053904)
10. Kuhn RJ, et al. (2002) Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell 108:717-725. (Pubitemid 34241430)
11. Sukupolvi-Petty S, et al. (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9227-9239.
12. Sukupolvi-Petty S, et al. (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816-12826. (Pubitemid 350156919)
13. Gromowski GD, et al. (2010) Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 407:237-246.
14. Wahala WM, et al. (2010) Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6:e1000821.
15. Brien JD, et al. (2010) Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84:10630-10643.
16. Shrestha B, et al. (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823.
17. Smith SA, et al. (2012) Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86(5): 2665-2675.
18. de Alwis R, et al. (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188.
19. DejnirattisaiW, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748.
20. Beltramello M, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283.
21. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM (2009) Dengue virus neutralization by human immune sera: Role of envelope protein domain IIIreactive antibody. Virology 392:103-113.
22. Oliphant T, et al. (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81:11828-11839. (Pubitemid 47623815)
23. Sánchez MD, et al. (2007) The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359:336-348. (Pubitemid 46290659)
24. Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM (2012) Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86:4019-4023.
25. Lok SM, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15:312-317.
26. Zhang W, et al. (2003) Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 10:907-912. (Pubitemid 37386099)
27. Li L, et al. (2008) The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science 319:1830-1834. (Pubitemid 351451591)
28. Gromowski GD, Barrett AD (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360. (Pubitemid 47398915)
29. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH (2011) The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29:7267-7275.
30. Valdés I, et al. (2011) The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol 18:455-459.
31. Kaufmann B, et al. (2010) Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci USA 107:18950-18955.
32. Vogt MR, et al. (2009) Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 83:6494-6507.
33. Spurrier B, et al. (2011) Structural analysis of human and macaque mAbs 2909 and 2.5B: Implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure 19:691-699.
34. Dias JM, et al. (2011) A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18:1424-1427.
35. Goncalvez AP, et al. (2008) Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol 82: 7009-7021. (Pubitemid 351977721)
36. Oliphant T, et al. (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80:12149-12159. (Pubitemid 44904366)
37. McMinn PC, et al. (1995) Murray valley encephalitis virus envelope protein antigenic variants with altered hemagglutination properties and reduced neuroinvasiveness in mice. Virology 211:10-20.
38. Mantel N, et al. (2011) Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 29:6629-6635.
39. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT (2011) Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29:7251-7260.
40. Kraus AA, MesserW, Haymore LB, de Silva AM(2007) Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45:3777-3780. (Pubitemid 350156883)